Last reviewed · How we verify
Carvedilol extended release only
Carvedilol extended release is a beta-blocker that works by blocking the effects of the hormone epinephrine, also known as adrenaline, and by slowing the heart rate and reducing its workload.
Carvedilol extended release is a beta-blocker that works by blocking the effects of the hormone epinephrine, also known as adrenaline, and by slowing the heart rate and reducing its workload. Used for Hypertension, Heart failure.
At a glance
| Generic name | Carvedilol extended release only |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Non-selective beta-blocker |
| Target | Beta-1 and beta-2 adrenergic receptors |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 2 |
Mechanism of action
Carvedilol extended release is a non-selective beta-blocker that also has alpha-1 adrenergic blocking activity. This allows it to reduce blood pressure and heart rate, while also reducing the workload on the heart.
Approved indications
- Hypertension
- Heart failure
Common side effects
- Dizziness
- Fatigue
- Headache
- Nausea
- Diarrhea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Carvedilol extended release only CI brief — competitive landscape report
- Carvedilol extended release only updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI